

<div style="display: flex; align-items: center;"><div style="writing-mode: vertical-rl; transform: rotate(180deg); font-weight: bold; margin-right: 5px;">09/10/99</div><div style="text-align: center;">UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 CFR 1.63(b))</small></div></div>	Attorney Docket No. 724/P10-258981	Total Pages :
	First Named Inventor or Application Identifier	
	Toshimitsu ISHIKAWA et al.	
	Express Mail Label No.:	

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents.</small>	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231
<div style="display: flex;"><div style="flex: 1;"><p>1. <input checked="" type="checkbox"/> Fee Transmittal Form <small>(Submit an original, and a duplicate for fee processing)</small></p><p>2. <input checked="" type="checkbox"/> Specification [Total Pages -16] <small>(preferred arrangement set forth below)</small></p><ul style="list-style-type: none">- Descriptive title of the Invention- Cross References to Related Applications- Statement Regarding Fed sponsored R & D- Reference to Microfiche Appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings <i>(if filed)</i>- Detailed Description- Claim(s)- Abstract of the Disclosure<p>3. <input type="checkbox"/> Drawing(s) <small>(35 USC 113)</small> [Total sheets -]</p><p>4. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages - 2]</p><div style="margin-left: 20px;"><p>a.1. <input checked="" type="checkbox"/> Newly executed (original or copy)</p><p>a.2. <input type="checkbox"/> Unexecuted</p><p>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 17 completed)</small> [Note Box 5 below]</p><p>i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p></div><p>5. <input type="checkbox"/> Incorporation By Reference <small>(usable if Box 4b is checked)</small> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p></div><div style="flex: 1; border-left: 1px solid black; padding-left: 5px;"><p>6. Microfiche Computer Program <i>(Appendix)</i></p><p>7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i></p><div style="margin-left: 20px;"><p>a. <input type="checkbox"/> Computer Readable Copy</p><p>b. <input type="checkbox"/> Paper Copy (identical to computer copy)</p><p>c. <input type="checkbox"/> Statement verifying identity of above copies</p></div></div></div>	ACCOMPANYING APPLICATION PARTS
<p>17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior Application No.</p>	<div style="margin-bottom: 10px;"><p>8. <input checked="" type="checkbox"/> Assignment Papers (cover sheet & document(s))</p><p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <small>(when there is an assignee)</small></p><p>10. <input type="checkbox"/> English Translation Document <i>(if applicable)</i></p><p>11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p><p>12. <input type="checkbox"/> Preliminary Amendment</p><p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small></p><p>14. <input checked="" type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired</p><p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small></p><p>16. <input checked="" type="checkbox"/> Other Claim for Small Entity Status and Change of Address</p></div>

18. CORRESPONDENCE ADDRESS WENDEROTH, LIND & PONACK 2033 "K" Street, N.W. Suite 800 Washington, D.C. 20006 Phone: (202) 721-8200 Fax: (202) 721-8250 September 10, 1999

THIS OFFICE IS AUTHORIZED
TO ACCEPT ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Toshimitsu ISHIKAWA et al. : Attn: APPLICATION BRANCH
Serial No. New : Docket No. 724/P10-258981
Filed September 10, 1999 :
SOFT CAPSULE

CLAIM FOR SMALL ENTITY STATUS


Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Applicants hereby claim Small Entity Status for this application, based on the attached
VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37
CFR 1.9 (f) and 1.27 (c)) - SMALL BUSINESS CONCERN.

Respectfully submitted,

Toshimitsu ISHIKAWA et al.

By 
Michael R. Davis
Registration No. 25,134
Attorney for Applicants

MRD/jk
Washington, D.C.
Telephone (202) 721-8200
Facsimile (202) 721-8250
September 10, 1999

660760 " 89T E 6 E 60

Applicant or Patentee: _____ Attorney's
Serial or Patent No.: _____ Docket No.: _____
Filed or Issued: _____
For: _____

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9 (f) and 1.27 (c)) — SMALL BUSINESS CONCERN

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN SANKYO CO., LTD.

ADDRESS OF CONCERN 2362-1, Oobuchi, Fuji-shi, Shizuoka, Japan

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9 (d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled SOFT CAPSULE

Toshimitsu ISHIKAWA et al. by inventor(s)
described in

☒ the specification filed herewith

☐ application serial no. _____, filed _____

☐ patent no. _____, issued _____

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9 (d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9 (d) or a nonprofit organization under 37 CFR 1.9 (e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME _____

ADDRESS _____

☐ INDIVIDUAL

☐ SMALL BUSINESS CONCERN

☐ NONPROFIT ORGANIZATION

NAME _____

ADDRESS _____

☐ INDIVIDUAL

☐ SMALL BUSINESS CONCERN

☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28 (b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Toshimitsu ISHIKAWA

TITLE OF PERSON OTHER THAN OWNER President

ADDRESS OF PERSON SIGNING c/o SANKYO CO., LTD., 2362-1, Oobuchi, Fuji-shi, Shizuoka, Japan

SIGNATURE Toshimitsu Ishikawa DATE September 2, 1999

TITLE OF THE INVENTION

SOFT CAPSULE

BACKGROUND OF THE INVENTION

5 This invention relates to a soft capsule, and more particularly to a soft capsule for foods, pharmaceuticals, cosmetics or the like.

10 Conventionally, a capsule has been commercially available in the art which is constructed in such a manner that a fat and oil material, an oil-soluble material, an oil-soluble perfume, and/or the like are charged or encapsulated in an encapsulating material made of gelatin. Such a capsule permits any ingredient in any desired amount to be readily provided or each dose to be handy to carry. Also, the capsule effectively prevents contact of an encapsulated ingredient with an ambient atmosphere, to thereby ensure stability of the ingredient.

15 A medicinal liquid which is an ingredient or material encapsulated in a soft capsule is constituted of a first medicinal liquid ingredient of a fat and oil material and a second medicinal liquid ingredient obtained by adding an effective component extract and/or an effective component powder to a fat and oil material to prepare a mixture and stabilizing the mixture with a suitable emulsifier. Then, the medicinal liquid thus obtained is charged or encapsulated in a soft
20 encapsulating material, resulting in the soft capsule being provided. Methods of producing soft capsules include techniques using a rotary type capsule manufacturing equipment, a seamless type capsule manufacturing equipment and a flat plate type capsule manufacturing equipment.

25 Unfortunately, the soft capsule manufactured by the conventional procedure causes much time to be required for preparation of the medicinal liquid or stock solution, leading to

a deterioration in both workability and productivity and an increase in production cost. Also, it tends to cause excessive intake of calorie because of containing a relative large amount of fats and oils.

5

SUMMARY OF THE INVENTION

The present invention has been made in view of the foregoing disadvantages of the prior art while taking notice of the fact that formulation of a dietary fiber in a prescribed amount in a medicinal liquid of a soft capsule permits the soft capsule to exhibit desired performance or characteristics.

10

Accordingly, it is an object of the present invention to provide a soft capsule which is completely free of such fats and oils and emulsifier or which has a minimum content of such fats and oils and emulsifier as contained in a conventional soft capsule.

15

It is another object of the present invention to provide a soft capsule which is capable of permitting a calorie intake due to taking of the soft capsule to be significantly restrained while ensuring concurrent intake of a dietary fiber.

20

It is a further object of the present invention to provide a soft capsule which is capable of being increased in productivity and reduced in manufacturing cost.

In accordance with the present invention, a soft capsule is provided. The soft capsule contains a dietary fiber in an amount of 5 to 90% by weight based on a whole composition of a medicinal liquid of the soft capsule.

25

In a preferred embodiment of the present invention, the dietary fiber is contained in an amount of 5 to 60% by weight based on the whole composition of the medicinal liquid.

30

In a preferred embodiment of the present invention, the dietary fiber is either a micronized vegetable fiber or a water-

soluble dietary fiber.

In a preferred embodiment of the present invention, the soft capsule is substantially free of any dispersion stabilizer.

In a preferred embodiment of the present invention, the soft capsule is substantially free of any fat and oil material or oil-soluble material.

In a preferred embodiment of the present invention, the soft capsule may further contain either a fat and oil material or an oil-soluble material in an amount of 50% or less by weight based on the whole composition of the medicinal liquid.

In a preferred embodiment of the present invention, the soft capsule may further contain a material of limited oil-solubility in an amount of 1 to 80% by weight based on the whole composition of the medicinal liquid.

In a preferred embodiment of the present invention, the soft capsule may further contain a material of limited oil-solubility in an amount of 1 to 70% by weight based on the whole composition of the medicinal liquid, wherein the fat and oil material or oil-soluble material is contained in an amount of 1 to 50% by weight based on the whole composition of the medicinal liquid.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

One of features of a soft capsule according to the present invention is that it contains a dietary fiber in an amount of 5 to 90% by weight based on a whole composition of a medicinal liquid for the soft capsule.

The dietary fiber is preferably a micronized vegetable fiber or a water-soluble dietary fiber, unlike a conventional dietary fiber. Such a dietary fiber is commercially available as a food stock at a reduced cost, resulting in being readily provided.

5 The dietary fiber is incorporated or contained in an amount of 5 to 90% by weight based on the whole composition of the medicinal liquid for the soft capsule. Such a content of the dietary fiber leads to preparation of a satisfactory suspended stock solution. Preferably, a content of the dietary fiber is 5 to 60% by weight. The content permits the suspended stock solution to be increased in stability.

10 Materials formulated in the medicinal liquid of the soft capsule include any desired powder material, extract material, fat and oil material which are conventionally formulated in foods, pharmaceuticals or cosmetics.

5 Powder materials of poor or limited oil-solubility and soft extract materials of poor or limited oil-solubility suitable for use in the present invention include chitosan, a water-soluble vitamin, an animal powder, a vegetable powder, a dietary fiber, an extract powder of a crude drug, an animal extract, a vegetable extract, a mineral and the like.

10 The powder material of limited oil-solubility, which has an average particle size sufficient to permit the material to pass through a screen of 60 to 200 meshes, and the soft extract material of limited oil-solubility, which has a water and alcohol content of 50% or less, are preferably formulated in an amount of 1 to 70% by weight based on the whole composition of the contents of the soft capsule. More preferably, they are formulated in an amount of 5 to 60% by weight.

25 A reduction in amount of the powder material and soft extract material of limited oil-solubility formulated facilitates manufacturing of the soft capsule, however, it brings about a disadvantage of causing an increase in intake of the soft capsule because it is required to take the materials in an amount sufficient to permit the materials to exhibit desired effects. Formulation of the materials in an amount above 50% by weight

causes manufacturing of the soft capsule to be complicated and workability to be deteriorated. Also, it leads to a deterioration in stability of the suspended stock solution.

In the soft capsule of the present invention, the medicinal liquid is substantially free of any emulsifying agent. The term "substantially free" used herein indicates both a case that the medicinal liquid does not contain any emulsifying agent and a case that it contains the agent in a concentration substantially decreased as compared with the conventional soft capsule.

The soft capsule of the present invention may contain a fat and oil material and an oil-soluble material. Alternatively, it may not contain the materials. When the soft capsule of the present invention is free of the fat and oil material and oil-soluble material, the materials are fully replaced with a dietary fiber. In this instance, this causes a problem that the soft capsule exhibits no effects of the fat and oil material and oil-soluble material, however, it permits a calorie intake derived from the fat and oil material to be substantially restrained and intake of a dietary fiber to be increased. Also, the soft capsule of the present invention permits a content of the fat and oil material and oil-soluble material to be significantly reduced as compared with the conventional soft capsule, even when it contains the materials.

Also, the fat and oil material (edible fat and oil) and oil-soluble material which may be contained in the soft capsule of the present invention include animal and vegetable edible fats and oils such as borage oil, evening primrose oil, perilla oil, refined fish oil containing DHA and/or EPA, liver oil, olive oil, safflower oil, egg yolk oil and the like; as well as oil-soluble materials such as vitamin E, vitamin A, vitamin D, carotenoid and the like.

5 The fat and oil material and oil-soluble material are preferably formulated in an amount of 1 to 50% by weight based on the whole composition of the contents of the soft capsule of the present invention. A stock solution contained or encapsulated in the soft capsule which is suspended by formulation of the powder material of limited oil-solubility, soft extract material of limited oil-solubility, dietary fiber and oil-soluble material exhibits increased stability as compared with any suspended stock solution conventionally commercially available.

10 An encapsulating material of the soft capsule is generally constituted of a combination of gelatin, glycerine, sugar and the like. Other ingredients which may be incorporated in the encapsulating material include eggshell calcium, alginic acid, sodium alginate, caramel, carrageenin, starch, flavor and the like.

15 The suspended stock solution encapsulated in the soft capsule of the present invention may be prepared by blending the powder material/soft extract material of limited oil-solubility with the dietary fiber and the fat and oil material/oil-soluble material to form a mixture and then subjecting the mixture to agitation for 20 to 30 minutes using a high-speed agitator, such as an agitator commercially available under a trade name "HOMO JETTOR" from TOKUSHU KIKI KOGYO CO., LTD. or the like, or a high-speed grinder, resulting in the mixture being homogenized.

20 During the treatment, the high-speed grinder or high-speed agitator is set at a rotational speed of 4000 to 6000 rpm.

25 The suspended stock solution thus prepared exhibits increased stability due to action of the dietary fiber as compared with the conventional stock solution employing a suspension stabilizer (emulsion stabilizer) such as beeswax, glycerine fatty ester or the like.

30 Also, the suspended stock solution contained in the soft

capsule of the present invention permits manufacturing of the soft capsule to be highly improved and time required for the manufacturing to be substantially reduced. The soft capsule of the present invention thus manufactured effectively prevents leakage of the solution from a sealing portion of the encapsulating material and enhances stability with time, leading to an increase in quality.

As can be seen from the foregoing, the soft capsule of the present invention permits a content of the less oil-soluble powder material and less oil-soluble soft extract material therein to be significantly increased. Also, it may be substantially free of any fat and oil material and emulsifier or minimize a content thereof.

Further, the soft capsule of the present invention permits the material of limited oil-solubility and powder material of limited oil-solubility containing water in an increased concentration to be highly dispersed therein, resulting in its being increased in stability with time.

The invention will be understood more readily with reference to the following examples; however, the examples are intended to illustrate the invention and are not to be construed to limit the scope of the invention.

Prior to description of the examples, test procedures employed in the examples will be described.

Test procedure 1: Test on dispersion stability of suspended stock solution

The suspended stock solution prepared by formulation is charged in a transparent vessel made of glass and formed to have a diameter of about 1 cm and a depth of about 10 cm. Then it is stored in a constant temperature bath at a temperature of 50°C while being capped. Dispersion stability of the suspended stock

5 solution is observed after 24 hours, 48 hours, 72 hours, one month and three months. Also, the suspended stock solution is subjected to centrifuging at a speed of 3000 rpm for 1 minute while being charged in a test tube (Spitzglas) of a centrifuge, resulting in dispersion stability of the suspended stock solution being observed.

10 Test procedure 2: Test on stability of soft capsule having suspended stock solution encapsulated therein with time

15 The soft capsule having the suspended stock solution encapsulated therein is manufactured. About 100 such soft capsules are charged in a glass vessel and stored in a thermo-hygrostat at a temperature of 40°C and a humidity of 75% while being tightly capped, resulting in an appearance of the soft capsules, smell thereof, tone thereof, suspension thereof, leakage of liquid therefrom and the like being observed after one month, three months and six months.

20 Example 1

25 A suspended stock solution having a composition shown in Table 1 was prepared. A dietary fiber was added to a raw royal jelly to prepare a mixture, which was then subjected to homogenizing at a speed of 4000 rpm for 15 minutes by means of a high-speed agitator "HOMO JETTOR" while gradually increasing the speed to a level of 4000 rpm. The temperature was kept at about 40°C.

30 The thus-prepared suspended stock solution was subjected to degassing at a pressure of 720 mmHg. Then, the degassed suspended stock solution was treated by means of a rotary-type soft capsule manufacturing equipment, resulting in a suppository-type soft capsule being provided.

Comparative Example 1

Beeswax and glycerine fatty ester melted by heating so as to act as a dispersion stabilizer were added to a fat and oil material constituted by safflower oil to prepare a mixture, which was then subjected to homogenizing at a temperature of $65 \pm 2^{\circ}\text{C}$ and a speed of 6000 rpm for about 20 minutes by means of a high-speed agitator "HOMO JETTOR" while gradually increasing a speed of the agitator to 6000 rpm, resulting in an intermediate suspended stock solution homogenized being obtained.

Thereafter, the intermediate suspended stock solution was cooled at a room temperature to 40°C or less, to thereby be rendered semisolid. Then, a raw royal jelly constituting a material of limited oil-solubility was added to the semisolid intermediate suspended stock solution while being kneaded into the intermediate suspended stock solution. This resulted in the intermediate suspended stock solution being ready to be treated by means of a high-speed agitator "HOMO JETTOR". Then, the agitator was gradually increased in rotational speed, to thereby permit the intermediate stock solution to be subjected to homogenizing at a speed of 6000 rpm for about 30 minutes, resulting in a suspended stock solution being prepared.

The suspended stock solution thus prepared was subjected to degassing at a pressure of 720 mmHg. Then, the degassed suspended stock solution was treated by means of a rotary-type soft capsule manufacturing equipment, resulting in a suppository-type soft capsule being provided.

Table 1

	Example 1	Comparative Example 1
Composition		
Fat and oil material:		
Safflower oil		168 mg
Material of limited oil-		
solubility:		
Raw royal jelly	180 mg	90 mg
Dispersion Stabilizer:		
Beeswax		21 mg
Glycerine fatty ester		21 mg
Dietary fiber	120 mg	
Total	300 mg	300 mg
Fat and oil material (%)		56
Material of limited oil-		
solubility (%)	60	30
Dietary fiber (%)	40	
Dispersion stabilizer (%)		14
Total (%)	100	100
Stability of suspended stock solution		
Temperature of 50°C	No separation	Slight separation
Centrifuging	No separation	Separation
Workability	Good	Poor
Liquid leakage	No	Yes
Stability with time (Appearance, smell, tone)	Good	Nasty smell
Suspension	No separation	Tendency to separate

Example 1 and Comparative Example 1 clearly indicate that containing of the raw royal jelly in an increased amount causes

much difficulty.

5 A content of a raw royal jelly in the conventional soft capsule is generally up to 30%. However, Example 1 indicates that the soft capsule of the present invention permits the raw
10 royal jelly to be contained in an amount as high as 60% by adding the dietary fiber. Also, Example 1 indicates that the present invention permits the suspended stock solution increased in suspension stability to be prepared without incorporating any fat and oil material and any suspension stabilizer such as beeswax,
15 glycerine fatty ester or the like in the suspended stock solution. Further, it indicates that the present invention permits the suspended stock solution to be encapsulated in the soft capsule while being significantly increased in both stability with time and quality.

Example 2

20 A suspended stock solution having a composition shown in Table 2 was prepared. A fat and oil material and a dietary fiber were homogenized together to prepare a homogenized mixture in a manner similar to that in Example 1 and then a material of limited oil-solubility was added to the mixture, resulting in the suspended stock solution being provided. Then, a soft capsule of the present invention was manufactured in which the thus-prepared
25 suspended stock solution was encapsulated. Though a content of the material of limited oil-solubility exceeded 50% of the composition of the medicinal liquid, the soft capsule exhibited improved workability, increased sealing properties, increased stability with time and enhanced suspension stability and was kept from any liquid leakage.

Table 2

Example 2

Composition

Fat and oil material:

Vegetable oil	15 mg
---------------	-------

Material of limited oil-solubility:

Gimnema sylvesta powder	210 mg
-------------------------	--------

Dietary fiber	30 mg
---------------	-------

Water	45 mg
-------	-------

Total	300 mg
-------	--------

Fat and oil material	5 %
----------------------	-----

Material of limited oil-solubility	70 %
------------------------------------	------

Dietary fiber	10 %
---------------	------

Water	15 %
-------	------

Total	100 %
-------	-------

Suspension stability

Temperature of 50°C	No separation
---------------------	---------------

Centrifuging	No separation
--------------	---------------

Workability	Good
-------------	------

Liquid leakage	No
----------------	----

Stability with time	Good
---------------------	------

(Appearance, smell, tone)

Suspension	No separation
------------	---------------

While the present invention has been described with a certain degree of particularity, obvious modifications and variations are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

What is Claimed is:

1. A soft capsule comprising a dietary fiber in an amount of 5 to 90% by weight based on a whole composition of a medicinal liquid of said soft capsule.

2. A soft capsule as defined in claim 1, wherein said dietary fiber is contained in an amount of 5 to 60% by weight based on the whole composition of said medicinal liquid.

3. A soft capsule as defined in claim 1, wherein said dietary fiber is either a micronized vegetable fiber or a water-soluble dietary fiber.

4. A soft capsule as defined in claim 2, wherein said dietary fiber is either a micronized vegetable fiber or a water-soluble dietary fiber.

5. A soft capsule as defined in claim 1, wherein said soft capsule is substantially free of any dispersion stabilizer.

6. A soft capsule as defined in claim 2, wherein said soft capsule is substantially free of any dispersion stabilizer.

7. A soft capsule as defined in claim 3, wherein said soft capsule is substantially free of any dispersion stabilizer.

8. A soft capsule as defined in claim 4, wherein said soft capsule is substantially free of any dispersion stabilizer.

9. A soft capsule as defined in claim 1, wherein said soft capsule is substantially free of any fat and oil material or oil-soluble material.

10. A soft capsule as defined in claim 2, wherein said soft capsule is substantially free of any fat and oil material or oil-soluble material.

11. A soft capsule as defined in claim 3, wherein said soft capsule is substantially free of any fat and oil material or oil-soluble material.

12. A soft capsule as defined in claim 5, wherein said soft capsule is substantially free of any fat and oil material or

oil-soluble material.

13. A soft capsule as defined in claim 1, further comprising either a fat and oil material or an oil-soluble material in an amount of 50% or less by weight based on the whole composition of said medicinal liquid.

14. A soft capsule as defined in claim 2, further comprising either a fat and oil material or an oil-soluble material in an amount of 50% or less by weight based on the whole composition of said medicinal liquid.

15. A soft capsule as defined in claim 3, further comprising either a fat and oil material or an oil-soluble material in an amount of 50% or less by weight based on the whole composition of said medicinal liquid.

16. A soft capsule as defined in claim 5, further comprising either a fat and oil material or an oil-soluble material in an amount of 50% or less by weight based on the whole composition of said medicinal liquid.

17. A soft capsule as defined in claim 9, further comprising a material of limited oil-solubility in an amount of 1 to 80% by weight based on the whole composition of said medicinal liquid.

18. A soft capsule as defined in claim 14, further comprising a material of limited oil-solubility in an amount of 1 to 70% by weight based on the whole composition of said medicinal liquid;

said fat and oil material or oil-soluble material being contained in an amount of 1 to 50% by weight based on the whole composition of said medicinal liquid.

19. A soft capsule consisting essentially of:

a dietary fiber in an amount of 5 to 90% by weight based on a whole composition of a medicinal liquid of said soft capsule; and

650300

5

DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATIONS

(X) Original () Supplemental () Substitute () PCT () DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: SOFT GAPSULE

which is described and claimed in:

(X) the attached specification, or
 () the specification in the application Serial No. _____ filed _____;
 and with amendments through _____ (if applicable),
 () the specification in International Application No. PCT/ _____, filed _____,
 and as amended on _____ (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	10-258981	September 11, 1998	(X) YES () NO
			() YES () NO
			() YES () NO
			() YES () NO
			() YES () NO
			() YES () NO

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

SERIAL NO.	U.S. FILING DATE	STATUS
		() Patented () Pending () Abandoned
		() Patented () Pending () Abandoned
		() Patented () Pending () Abandoned

And I hereby appoint V. M. Creedon, Reg. No. 17111, John T. Miller, Reg. No. 21120, John T. Fedigan, Reg. No. 24347, Michael R. Davis, Reg. No. 25134, Matthew M. Jacob, Reg. No. 25154, Jeffrey Noltan, Reg. No. 25408, and Henry M. Zykorie, Reg. No. 27477, who together constitute the firm of WENDEROTH, LIND & PONACK, jointly and severally, attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys named herein to accept and follow instructions from KAMMON INTERNATIONAL as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Send Correspondence to:

Direct Telephone Calls to:

WENDEROTH, LIND & PONACK
 Southern Building - Suite 700
 805 Fifteenth Street, N.W.
 Washington, D.C. 20005

WENDEROTH, LIND & PONACK
 Area Code (202) 371-8850

660160 " 89126660

FULL NAME OF 1ST INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	ISHIKAWA	Toshimitsu	
RESIDENCE & CITIZENSHIP	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
	Shizuoka	Japan	Japan
POST OFFICE ADDRESS	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
	1327-2, Atsuhara, Fuji-shi, Shizuoka, Japan		
FULL NAME OF 2ND INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	WADA	Nobuyuki	
RESIDENCE & CITIZENSHIP	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
	Shizuoka	Japan	Japan
POST OFFICE ADDRESS	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
	634-8, Denbou, Fuji-shi, Shizuoka, Japan		
FULL NAME OF 3RD INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	KAWAGUCHI	Futao	
RESIDENCE & CITIZENSHIP	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
	Shizuoka	Japan	Japan
POST OFFICE ADDRESS	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
	1485-1, Denbou, Fuji-shi, Shizuoka, Japan		
FULL NAME OF 4TH INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	KAJIMA	Koji	
RESIDENCE & CITIZENSHIP	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
	Shizuoka	Japan	Japan
POST OFFICE ADDRESS	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
	358-1-101, Nakajima, Fuji-shi, Shizuoka, Japan		
FULL NAME OF 5TH INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
RESIDENCE & CITIZENSHIP	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
FULL NAME OF 6TH INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
RESIDENCE & CITIZENSHIP	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Toshimitsu Ishikawa Date September 2, 1999
 2nd Inventor Nobuyuki Wada Date September 2, 1999
 3rd Inventor Futao Kawaguchi Date September 2, 1999
 4th Inventor Koji Kajima Date September 2, 1999
 5th Inventor _____ Date _____
 6th Inventor _____ Date _____

The above application may be more particularly identified as follows:

U. S. Application Serial No. P10-258981/AM/ Filing Date _____
 Applicant Reference Number SAN/US Atty Docket No. _____
 Title of Invention SOFT CAPSULE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Toshimitsu ISHIKAWA et al. : Attn: APPLICATION BRANCH
Serial No. New : Docket No. 724/P10-258981
Filed September 10, 1999 :
SOFT CAPSULE

CHANGE OF ADDRESS

Assistant Commissioner for Patents
Washington, DC 20231


Sir:

Effective immediately, please note the following change of address for the undersigned attorney of record:

WENDEROTH, LIND & PONACK, L.L.P.
2033 "K" Street N.W.
Suite 800
Washington, D.C. 20006

Respectfully submitted,

Toshimitsu ISHIKAWA et al.

By 
Michael R. Davis
Registration No. 25,134
Attorney for Applicants

MRD/jk
Washington, D.C.
September 10, 1999

660T60"33T6660